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Extracellular vesicles are a heterogeneous group of cell-derived membranous structures,
which facilitate intercellular communication. Recent studies have highlighted the
importance of extracellular vesicles in bone homeostasis, as mediators of crosstalk
between different bone-resident cells. Osteoblasts and osteoclasts are capable of
releasing various types of extracellular vesicles that promote both osteogenesis, as
well as, osteoclastogenesis, maintaining bone homeostasis. However, the contribution
of immune cell-derived extracellular vesicles in bone homeostasis remains largely
unknown. Recent proteomic studies showed that alarmins are abundantly present in/on
macrophage-derived EVs. In this review we will describe these alarmins in the context of
bone matrix regulation and discuss the potential contribution macrophage-derived EVs
may have in this process.
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INTRODUCTION
Intercellular communication is an important biological process which allows cells to coordinate
their response to physiological changes, environmental triggers and pathogenic invaders in a spatial
and temporal fashion. A new addition to the intercellular communication system are extracellular
vesicles (EVs) (1). EVs are small cell membrane-derived phospholipid bilayer structures that range
in diameter from 30 to 2000 nm. Previously, they were considered to be merely cellular waste
products, nowadays EVs are recognized as regulatory structures, produced and released by an
actively regulated intracellular and energy dependent process as a means to shuttle complex cargo
and deliver biological information to recipient cell/tissues. A distinction can be made between
three different subtypes of vesicles based on their biogenesis and size: exosomes (30–150 nm
diameter) released by exocytosis, microvesicles or microparticles (100–1,500 nm diameter) formed
by budding from the plasma membrane (shedding vesicles, matrix vesicles) and apoptotic bodies
(500–2,000 nm diameter) released from apoptotic cells (2).While the latter are the specific products
of the complex processes of cells undergoing programmed cell death, all other EV subtypes are not
phenotypically linked to cell death.
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Upon release, EVs can interact with recipient cells in a
number of ways. Host receptor activation can be induced
via the interaction of vesicle membrane proteins either in a
juxtacrine fashion or by paracrine signaling after being cleaved
and released from EVs. EVs can also fuse with the cell
membrane, mediating membrane receptor transfer and releasing
its cargo intracellularly. Finally, EVs can be taken up by cells
via endocytosis, delivering their cargo inside endocytic vacuoles
(3). EV-mediated transfer of protein, genetic information (DNA,
RNA and predominately small non-coding RNA andmicroRNA)
is shown to be very efficient and intravesicular cargo is protected
from degradation in the intercellular environment by their lipid
bilayer membrane (4).
The involvement of EVs in bone homeostasis was previously
thought to be primarily via matrix vesicles, a specific subgroup
of EVs that consist of small membrane particles (20–200 nm),
which bud off from the plasma membrane of mineralizing cells,
such as osteoblasts and chondrocytes, prior to the onset of
matrix mineralization [reviewed in (5)]. Ultrastructural studies
in the late 1960’s have shown that cartilage calcification starts
in and around matrix vesicles, and matrix vesicles have since
been implicated to play a role in the calcification of bone,
cartilage, and dentin. However, more recent studies show the
importance of bone cell-derived EVs as mediators of intercellular
communication and their function in bone homeostasis and
remodeling [reviewed in (6)]. In this review we will briefly
summarize the communication between bone cells via EVs and
thereafter focus on the potential role of macrophage-derived EVs
carrying alarmins as contributors of bone remodeling.
THE FUNCTION OF EVs IN BONE
REMODELING EXTENDS THAT OF BEING
MATRIX PARTICLES
The skeleton physiology is not exempt from the participation of
EVs in biological processes. In fact, the skeleton houses a complex
microenvironment that hosts a great diversity of cells, such as
osteoblasts, osteoclasts, osteocytes, and other myeloid cells of
the bone marrow, including macrophages. All of these cells are
known to release EVs which can regulate each other’s function.
Osteoblasts
Osteoblasts are specialized mesenchymal cells that are
responsible for bone matrix synthesis and mineralization during
both initial bone formation and later bone remodeling. These
cells were first recognized to promote mineralization, releasing
matrix vesicles able to initiate nucleation of hydroxyapatite
crystals (7). Across the years, further investigations deeply
characterized the cargo and functions of matrix vesicles derived
from osteoblasts and osteoblast-like cells, identifying alkaline
Abbreviations: DAMP, damage-associated molecular pattern; EV, extracellular
vesicle; HSP, heat shock protein; M-CSF, macrophage colony-stimulating factor;
MSC,mesenchymal stem cell; NF-κB, activating nuclear factor-κB; RAGE, receptor
for advanced glycosylation end products; RANKL, receptor activator of nuclear
factor kappa-B ligand; RUNX2, runt-related transcription factor 2; TLR, toll-like
receptor.
phosphatase, the pyrophosphate generating enzyme PC1 and
the pyrophosphate channel ANK as key mechanisms causing
pyrophosphate production and influx into these EVs by
hydroxyapatite nucleation.
Primary osteoblasts and their EVs share a similar gene
profile, which included the expression of atf4, alp, runx2, osx,
col1a1 (8). A deeper proteomic characterization of exosomes
derived from osteoblastic cell line (MC3T3) revealed many
proteins related to the osteogenic pathways, such as mTOR,
integrins, and eukaryotic initiation factor-2 signaling (9).
Transcriptomic profiling performed in mineralizing MC3T3
revealed EVs containing osteogenic miRNAs (10). Exposure
of mouse bone marrow-derived stromal ST2 cells to MC3T3-
derived EVs, induced their osteogenic differentiation, manifested
by the up-regulation of osteogenic markers, such as runt-related
transcription factor 2 (RUNX2) and alkaline phosphatase, and
enhancing matrix mineralization through the modulation of
calcium, Wnt, insulin, and TGF-β signaling pathways.
van Leeuwen et al. studied the molecular profile of EVs
from human osteoblasts, both in naïve and mineralizing
conditions (11, 12). Comparing the cellular and EV mRNAs of
osteoblasts, they showed that EVs were enriched with mRNAs
related to protein translation, RNA processing and cell-to-cell
communication, in particular with osteoclasts (NFKBIB, PGF),
adipocytes (FGF1) and hematopoietic stem cells (FLT3LG, IL18)
(11). Taken together, these findings suggest that osteoblasts
release EVs capable of enhancing osteogenic differentiation,
thereby contributing to bone formation and mineralization.
Osteoclasts
Osteoclasts are unique in their ability to resorb bone and play
an important role in bone turnover. A tight crosstalk with
osteoblasts and osteocytes, which influence osteoclastogenesis
by the factors they produce, is crucial to synchronize the
activities in homeostatic bone remodeling (13, 14). Osteoclasts
differentiate from myeloid progenitor cells under the influence
of macrophage colony-stimulating factor (M-CSF) and receptor
activator of nuclear factor kappa-B ligand (RANKL) (15,
16). Next to RANKL signaling, a co-stimulatory signal is
required for osteoclastogenesis. After full differentiation, mature
multinucleated osteoclasts can start to secrete acids and lytic
enzymes that together resorb the bony tissues (14).
A recent study reported that osteoclast precursors are capable
of releasing exosomes that could directly promote the osteogenic
differentiation of the recipient mesenchymal stem cells (17).
On the other hand, Liu and colleagues showed that mature
osteoclast-derived exosomes were internalized by osteoblasts
leading to a miR-214-3p-dependent inhibition of osteoblast
activity and bone formation (18).
Interestingly, osteoclast EVs seemed to be involved in their
own maturation. Holliday’s group showed that pre-osteoclast
EVs promoted osteoclastogenesis in whole bone marrow stromal
cell cultures upon Vitamin D3 treatment, while mature osteoclast
EVs inhibited osteoclastogenesis in the same culture conditions
(19). This effect was demonstrated to be due to RANK expressed
by EVs only from mature osteoclasts, presumably able to bind
competitively RANKL in the microenvironment, similarly to
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osteoprotegerin (OPG). Furthermore, EVs from osteoclasts have
been shown to transfer osteoclast-osteoblast coupling factors.
RANK-expressing EVs from mature osteoclasts bind RANKL
on osteoblasts, activating the reverse signaling and inducing
RUNX2 activity in osteoblasts and bone formation (20). The idea
of EV-based osteoclast-to-osteoblast coupling is strengthened
by the paper of Sun et al. showing that EVs from osteoclasts
express EphrinA2, which binds the Eph receptor expressed by
osteoblasts, inhibiting bone formation (21, 22). These findings
highlight the importance of EVs in the communication between
osteoclasts and osteoblasts, but it is yet to be determined what
the relative contribution of the vesicles is compared to the total
secretome of these cells.
Osteocytes
Osteocytes, the end stage of osteoblast differentiation, are
matrix-embedded cells mainly involved in the regulation of
bone remodeling and in the adaptation to mechanical forces
(23). Morrel et al. found that mechanical stimulation activated
osteocyte network inducing Ca2+-dependent contractions and
enhancing the production and release of EVs containing RANKL,
OPG and sclerostin (SOST) (24).
In comparison to osteoblast- and osteoclast-derived EVs
much less is known about osteocyte-derived EVs. Osteocytes
produce a unique EV population, described by Sato et al. in the
osteocyte-ablated mouse model. They characterized circulating
EVs of osteocyte-less mice and found 12 downregulated miRNAs
in plasma. Furthermore, they described that this pool of
miRNAs was enriched in EVs from osteocyte-like MLO-Y4 cells
compared to non-osteocytic ST2 cells (25). Among the osteocyte
miRNAs is miR-218 which could be taken up by osteoblasts,
resulting in downregulation of SOST leading to osteogenic
activity (26).
Other Bone Interacting Cells
The balanced interplay between these three bone cell types is also
under control of immune cells like macrophages and T-cells and
often during inflammation the homeostatic situation is turned
into accelerated bone loss. These immune cells produce cytokines
that steer the differentiation of progenitor cells into osteoblasts or
osteoclasts thereby influencing bone regeneration.
Interestingly, the biogenesis of EVs is controlled by
intracellular Ca2+ concentrations in the EV-producing cells
and, furthermore, EVs are often carriers of calcium ions
contributing to calcification of tissues (27). As bone regulates
calcium homeostasis in the body, it may indirectly influence
EV biogenesis as well. Moreover, cytokines and growth factors
can alter intracellular Ca2+ levels by depleting calcium from
the endoplasmic reticulum and by increasing calcium influx
from the extracellular space. Hence, inflammation can regulate
both the extra- and intracellular Ca2+ levels and thereby
regulate EV biogenesis although many other intracellular
mechanisms are involved as well. In the next paragraphs we
will discuss how EVs derived from innate immune cells might
communicate with bone cells and regulate bone homeostasis
via alarmins.
MACROPHAGES AS A SOURCE FOR EVs
CARRYING ALARMINS
Macrophages are a highly heterogenous population derived
from the myeloid linage that can reside in bone either as
resident cells or as a result of recruited myeloid precursors,
mainly monocytes, that differentiate in the tissue. The interplay
between macrophages and bone cells is critical to bone
formation and repair. Osteal macrophages, also known as
osteomacs, are one of these resident macrophages located
in close proximity to the bone surface and do not express
TRAP (28). However, they colocalize with TRAP positive
osteoclasts and are found immediately adjacent or near to
giant osteoclasts at catabolic sites (29). Osteomacs are also
tightly associated with osteoblasts in the endosteal and the
periosteal surface. When osteoblasts undergo apoptosis they
are phagocytosed together with the debris by neighboring
osteomacs (28). Osteomacs have also been shown to support
bone formation and osteoblast mineralization in vitro
and in vivo using a mouse model in which macrophages
were ablated (MaFIA, macrophage Fas-induced apoptosis
mouse) (28).
Apart from being crucial in homeostasis of normal bone,
macrophages also play a critical role in inflammation-driven
bone diseases (30). Tissue damage elicited by external (injuries,
chemicals, infection) and internal triggers (DNA damage,
immunological reactions) or by shortage (nutrients, oxygen) or
excess (sugar, cholesterol) of factors can induce macrophage
activation that disturbs bone homeostasis and causes bone
destruction. Most of the damage associated factors are first
sensed by resident macrophages that become stressed and upon
activation recruit more macrophages. Resident and recruited
macrophages respond to their local environment and activate
specific transcriptional programs that drive them to a spectrum
of different phenotypes ranging from pro-inflammatory M-1
like to anti-inflammatory M-2 like macrophages (31). When
macrophages become stressed, pro- and anti-inflammatory
mediators are released into the micro milieu that regulate innate
and adaptive immune cells and may cause disbalanced bone
homeostasis (32).
The majority of pro-inflammatory factors that are released
by macrophages are rapidly suppressed by many feedback
mechanisms. However, EVs are able to deliver pro-inflammatory
factors to other cells in a protected way (33). Nevertheless,
not all secreted proteins detected in the medium are also
present in the EVs since packaging of the biomolecular cargo
within the macrophage EVs is a regulated process (34). LPS
stimulated macrophages release interleukins in the medium that
were absent in their exosomes (35). On the other hand, many
alarmins, damage-associated molecular patterns (DAMPs), are
present in macrophage-derived EVs. For example, New et al.
showed that macrophage-derived EVs are enriched in S100A9
and Anx5 and contribute to microcalcifications observed in
atherosclerotic plagues (36). Using gain- and loss-of-function
experiments the authors reveal the critical role for Anx5-S100A9
complexes in this process, highlighting the functional activity of
EV-carried alarmins.
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Alarmins
Alarmins are endogenous molecules that are constitutively
available and released upon cellular stress and activate the
immune system, causing inflammation in vivo. Many alarmins
are intracellular proteins that are both passively and actively
secreted. Passive release is often associated with cell injury
or death, whereas active release is regulated by mechanisms
independent of ER-Golgi routes, such as degranulation or
pyroptosis. Upon release, alarmins can bind a range of receptors
among which toll-like receptors (TLRs) and receptors for
advanced glycosylation end products (RAGE) are the most
studied (37).
Proteomic studies on both monocyte- and macrophage-
derived EVs show the presence of a large variety of alarmins,
including annexins, galectins, heat-shock proteins and S100-
alarmins (38–47). An overview of EV-associated alarmins
is presented in Table 1. Within these studies different
EV-populations were studied, ranging from exosomes to
microparticles. Differential ultracentrifugation protocols were
used for most studies, either in combination with density
gradient or precipitation techniques. Most alarmins were present
in the majority of the studies, including HSP-90, annexins, and
several S100-proteins. Simultaneously, part of the alarmins were
only found in a limited number of studies. These observed
differences could be due to the different isolation methods,
EV-subtypes investigated or sensitivity of the proteomic analysis.
Recruitment of alarmins into EVs seems to be partially
dependent on the macrophage activation state. Stimulation
of macrophages with curdlan, a bacterial β-glucan, increased
vesicle-mediated protein secretion, and specifically increased
the amount of alarmins found in their EVs (38). Similarly,
infection of macrophages with influenza A virus, resulted in
an increase in alarmins found in their produced EVs (39). It
remains to be investigated whether polarization of macrophages
also changes alarmin expression of their EVs, it has however been
shown that microvesicles produced by M1 and M2 macrophages
contain different mRNAs that can identify the macrophage
phenotype (48).
From these proteomic studies it is not possible to determine
which of these alarmins are surface-accessible. As most receptors
recognizing alarmins (TLRs, RAGE) sense the extracellular
milieu it is important which of these alarmins are carried on
the surface of EVs. A recent study by Cvjetkovic et al. presented
a novel work-flow designed to identify proteins localized on
the surface of EVs (49). Using a multiple proteomics approach,
combining proteinase treatment and biotin tagging, they were
able to identify many proteins of cytosolic origin that were
localized on the surface of mast cell-derived EVs. Among
the identified proteins were a number of alarmins, including
nucleolin, S100-A9, -A10, -A13, galectin-1, and several heat
shock proteins. Interestingly, all annexins (A1-A7, A11, and
A13) were absent from the surface, and were instead present
intravesicularly (49). In contrast, Stewart, et al. showed that
annexin-2 is localized on the surface of EVs (50). These
discrepancies could be due to the different cell types used and
the different sub-groups of EVs investigated. Microvesicles seem
to more predominant in their surface expression of annexin-V
TABLE 1 | List of alarmins found by proteomic analysis of monocyte and
macrophage-derived EVs.
Vesicle subtype References
Heat-shock proteins
Heat shock conjugate 71
kDa
Exosomes, microparticle,
microvesicles
(38, 39, 41, 42, 44–47)
HSP-β1 Exosomes, microparticle (38, 39, 43–45, 47)
HSP-70 (protein 1A) Exosomes, microparticle (38, 39, 41, 43–45, 47)
HSP-70 (protein 4) Exosomes, microparticle (39–42, 44, 45, 47)
HSP-70 (protein 13) Exosomes (39, 41, 42)
HSP-75, mitochondrial Exosomes, microparticle (39, 41, 43, 44, 47)
HSP-90α Exosomes, microparticle,
microvesicles
(38–42, 44–47)
HSP-90β Exosomes, microparticle,
microvesicles
(38–47)
HSP-105 Exosomes, microparticle (39, 41–47)
10 kDa heat shock
protein
Exosomes, microparticle (38, 39, 41, 42, 44, 45,
47)
60 kDa heat shock
protein
Exosomes, microparticle (39, 41–47)
Annexins
Annexin A1 Exosomes, microparticle (38–45, 47)
Annexin A2 Exosomes, microparticle (38–45, 47)
Annexin A3 Exosomes, microparticle (39–42)
Annexin A4 Exosomes, microparticle (38–43, 45, 47)
Annexin A5 Exosomes, microparticle,
microvesicles
(38, 39, 41–47)
Annexin A6 Exosomes, microparticle,
microvesicles
(38–41, 43–47)
Annexin A7 Exosomes, microparticle (38, 39, 41–45, 47)
Annexin A11 Exosomes, microparticle (38–41, 43–45, 47)
Galectins
Galectins-1 Exosomes, microparticle (38, 39, 41, 42, 45, 47)
Galectin-3 Exosomes, microparticle (39, 41, 42, 45, 47)
Galectin-7 Exosomes, microparticle (38, 39, 44, 47)
Galectin-9 Exosomes, microparticle (38, 39, 47)
Galectin-9B Exosomes, microparticle (39, 45)
S100-alarmins
S100-A4 Exosomes, microparticle (38, 39, 41, 42, 45, 47)
S100-A6 Exosomes, microparticle (38, 39, 41, 42, 45, 47)
S100-A8 Exosomes, microparticle (38, 39, 45, 47)
S100-A9 Exosomes, microparticle (39, 45, 47)
S100-A10 Exosomes, microparticle (38, 39, 41, 42, 45, 47)
S100-A11 Exosomes, microparticle (38, 39, 41, 42, 45, 47)
S100-P Exosomes (39)
Miscellaneous
Cathelicidin Exosomes (39)
Defensin α3 Exosomes (39)
Endoplasmin Exosomes, microparticle (38, 39, 41–45, 47)
Fibronectin Exosomes, microparticle (38, 39, 42, 43, 45–47)
HMGB1 Exosomes, microparticle (41, 43, 45)
Nucleolin Exosomes, microparticle (39, 41–45, 47)
Thymosin β4 Exosomes, microparticle (39, 42, 45)
78 kDa glycoseregulated
protein
Exosomes (42)
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compared to exosomes, as demonstrated by Heijnen et al.
(51). The sorting mechanism responsible for protein localization
remains to be identified.
THE EFFECT OF ALARMINS ON
OSTEOBLASTS AND OSTEOCLASTS
Alarmins play wide roles in different cell types. Multiple studies
described the profound involvement of families of alarmins in
osteocyte, osteoblast and osteoclast differentiation and function,
including annexins, galactins, heat shock proteins, S100-proteins
and various other proteins, although detailed studies for many of
the individual family members are still lacking.
Annexins
Annexins are autocrine/paracrine factors secreted by several cell
types. Among them, Annexin 2 (AnxII) was demonstrated to
increase bone resorption (52). This effect was shown to be due to
activation of bone marrow stromal cells with the overexpression
of GM-CSF and RANKL, both being pro-osteoclastogenic factors
(53). Additionally, a previous study showed that overexpression
of AnxII stimulated osteoclast formation (54). Another study
poses that AnxII is only involved in the proliferation of
osteoclast precursors, probably via stimulation of GM-CSF
production, but not in the later multinucleation stages of
osteoclast differentiation (52). The receptor that mediates these
effects remains to be elucidated. However, most studies described
an autocrine effect of osteoclast-produced AnxII, leaving the
importance of macrophage-derived AnxII in the stimulation of
osteoclasts unknown.
Galectins
Galectins are a class of proteins that bind specifically to β-
galactoside sugars, consisting of 15 members, of which 9 are
known in humans and 11 in mice. These soluble proteins have
both intra- and extracellular functions (55).
Galectin-1 (Gal-1) has been proposed to mediate cell-to-cell
and cell-to-matrix adhesion (55). Furthermore, galectin-1 has
been found both to promote and inhibit cell proliferation of
a number of cells. In particular, Gal-1 was demonstrated to
decrease differentiation of bone marrow stromal cells (56).
Galectin 3 (Gal-3) is another member of the galectin family
found to affect both osteoblast and osteoclast differentiation.
It has been demonstrated that exogenous recombinant Gal-
3 inhibited terminal differentiation of a human pre-osteoblast
cell line (57). Weilner et al. found that Gal-3 affected
osteogenic differentiation of mesenchymal stem cells (MSCs)
and, interestingly, that Gal-3 can be detected in EVs from
plasma. Administration of Gal-3-EVs to MCSs increased
osteoblastogenesis, preventing β-catenin degradation (58). On
the other hand, Gal-3 strongly decreased osteoclast formation
from precursors by suppressing nuclear factor of activated T-
cells c1 (NFATc1), whereas Gal-3-deficient bone marrow cells
had an increased osteoclastogenic potential. Moreover, addition
to mature osteoclasts inhibited their resorptive capacity (59, 60).
Likewise, Gal-9 markedly decreased osteoclast formation from
cell lines and bone marrow cells, probably via binding to its
receptor T-cell immunoglobin- and mucin-domain-containing
molecule 3 (Tim-3) (61).
Heat Shock Proteins
Heat shock proteins (HSPs) are among the most well-studied
alarmins. Under physiological conditions they act as intracellular
chaperone proteins, but some members are secreted upon
stress. Stress factors such as IL-1β and TNFα have been
shown to increase HSP60 secretion. These increased HSP60
levels were shown to promote osteoclast formation and activity
via potentiation of RANK-RANKL signaling. The same study
showed that this effect runs via binding of HSP60 to TLR2 (62).
The finding that HSP60 is an agonist for the triggering receptor
expressed in myeloid cells (TREM)2 receptor, which is part of
the co-stimulatory signaling that is needed for osteoclastogenesis,
might give an additional mechanism of how HSP60 might
increase osteoclastogenesis (63).
In contrast, the HSP70 family member heat-shock 70-kDA
protein-8 binds to the ubiquitin-like protein monoclonal non-
specific suppressor factor β and double knockdown of these
factors inhibited RANKL-induced osteoclastogenesis (64). The
effects of HSP90 on osteoclastogenesis are more controversial.
Whereas, its inhibition with SNX-2112 potently inhibited
osteoclast formation (65), the effects of HSP90 inhibition with 17-
allylamino-17-demethoxygeldanamycin (17-AAG) on osteoclast
formation was shown to be cell-type dependent (66–68).
S100 Family Proteins
S100 proteins are low molecular weight proteins that belong
to the family of calcium binding proteins. Extracellular S100A4
binds to cell surface receptors, such as the RAGE, activating
nuclear factor-κB (NF-κB) (69). On mature murine osteoblasts,
S100A4 was shown to inhibit mineralization activity and the
expression of late-stage osteoblast markers via activation of the
NF-κB pathway (70). Additionally, S100A4 has been shown to
stimulate osteoclast formation (71). Moreover, although in vitro
osteoclast cultures with S100A4-deficient bone marrow resulted
in more TRAP+ cells compared to wild type cells, the formed
osteoclasts were much smaller with less nuclei, underlining the
importance for S100A4 in osteoclast formation (72). Finally,
binding of S100A4 to extracellular annexins has been shown
to regulate the fusogenic activity of osteoclasts (73). The most
well-studied S100 proteins in the context of inflammatory bone
diseases are S100A8 and S100A9, however data about their
direct function on osteoblasts and osteoclasts is rather limited.
A previous study showed that stimulation of mature murine
osteoclasts with S100A8 enhances their further fusion and
resorbing activity via binding to TLR4 (74). Another study
showed that S100A9 directly stimulates osteoclast formation
from monocytes in the context of osteomyelitis in the absence of
RANKL (75). However, addition of S100A9 to humanmonocytes
strongly inhibits osteoclast differentiation (76).
High Mobility Group box Protein 1
High mobility group box protein 1 (HMGB1) is a non-
histone nuclear protein that acts as an alarmin extracellularly.
TLR2/4/9 and RAGE have been implicated as receptors of
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extracellular HMGB1. HMGB1 release occurs during tissue
injury or microbial invasion via two major pathways, one
passive and the other active. Passive release is associated with
necrotic cell death, whereas during active release HMGB1 is first
shuttled to the cytoplasm, in a JAK-STAT dependent manner,
and is thereafter either released into the extracellular space
during pyroptosis or alternatively via exocytosis of secretory
lysosomes (77, 78). HMGB1 has also been found in EVs. For
lymphocytes it is primarily associated with apoptotic vesicles
(79), whereas, for macrophages it has also been shown in
vesicles released in response to TLR-activation (80). A function
for HMGB1 in bone homeostasis has been described, where
it can stimulate osteoclastogenesis. HMGB1-RAGE signaling
was shown to be important in regulating actin cytoskeleton
reorganization, thereby contributing to RANKL-induced and
integrin-dependent osteoclastogenesis (81).
Other Alarmins
Fibronectin also plays a crucial role in the differentiation of
osteoblasts (82). Fibronectin is a heterodimeric extracellular
matrix glycoprotein that has several cell- and matrix-binding
domains (83). Normal human and murine osteoblasts express
fibronectin receptors α3β1, α4β1, α5β1, αvβ3, and αvβ5
integrins (84–86). Fibronectin was shown to induce osteoblast
differentiation, since perturbation of binding between fibronectin
and osteoblasts suppressed nodule formation and maturation,
as well as alkaline phosphatase and osteocalcin expression
(82). Moreover, fibronectin also displayed pro-survival effect
on mature osteoblasts (87). In contrast, fibronectin inhibits the
formation of osteoclasts but stimulates the activity of mature
osteoclasts via nitric oxide and IL-1β-mediated pathways (88).
Finally, the antimicrobial peptide of the cathelicidin family LL-37
inhibits osteoclastogenesis by inhibiting the calcineurin activity
(89) and the actin-sequestering protein thymosin β4 suppresses
osteoclast differentiation (90).
SUMMARY AND PERSPECTIVE
The function of soluble alarmins has widely been studied, and
it is clear there is a profound involvement of alarmins in
bone-resident cell differentiation and function. A number of
these alarmins have also been identified on EVs derived from
monocytes/macrophages, and make up a sizable portion of
the vesicle cargo. We hypothesize that vesicle-carried alarmins
can have similar effects to soluble alarmins on osteoblast and
osteoclast differentiation and function and thereby contribute to
bone homeostasis (schematic cartoon in Figure 1).
The composition and relative quantities of alarmins on
monocyte/macrophage-derived EVs will ultimately determine
their function. Although functional studies are limited, as focus
is often on the vesicle as a whole rather than individual proteins
carried by the EV, a delicate study by New et al. revealed a critical
role of the alarmins Anx5 and S100A9 present on macrophage-
derived EVs in microcalcifications in atherosclerotic plaques
(36). An additional study, by Nair et al. has shown that
LPS stimulated macrophages release microvesicles coated with
histones, a different type of alarmin. These histones can interact
with TLR4 promoting inflammatory responses (91). On that
note, it is important to understand where alarmins are expressed,
either on the membrane surface or intravesicularly. Surface
bound alarmins can interact with membrane bound receptors
on the bone cells, such as TLRs or RAGE, whereas intravesicular
alarmins can only interact with intracellular receptors. The mode
of uptake is also important in this regard, as a portion of
engulfed vesicles are immediately degraded in the lysosome of the
recipient cell and therefore will not have to chance to release their
alarmins intravesicular.
EVs also contain different molecules such as lipids,
polymers of nucleotides, sugars, and other cell metabolites,
and when EVs are taken up these molecules will have an
impact on the bone cells as well. Nevertheless, alarmins on
EVs mediate their first direct contact with bone cells via
membrane receptor recognition and this interaction could
be an effective target to treat bone destruction. Secondly it
might be possible to steer either the expression of alarmins in
monocytes/macrophages or the EV-loading mechanism toward
EVs that possess an anti-inflammatory and bone inducing
phenotype. EVs are quite sturdy and can be transportation
via the circulation, which makes alarmin-EVs important
messengers in the local bone remodeling process also when
monocytes/macrophages are not in close proximity with
the bone cells. An important feature of EVs which enables
this distal communication is the ability to integrate with
extracellular matrix. Besides carrying alarmins, EVs carry
an abundance of adhesion molecules and can bind various
matrix molecules allowing interaction with bone (92). This
makes EVs uniquely equipped to function as a long-distance
alarmin-delivery system to osteoclasts and osteoblasts at the
bone site.
Our understanding of extracellular vesicles and alarmins as
regulators of bone homeostasis have greatly increased over the
past decade, however a role for alarmins on/in extracellular
vesicles is often overlooked. Clearly macrophages play a
role in bone remodeling and are a source of vesicle-carried
alarmins. Future studies should be directed to determine the
contribution macrophage-derived EVs have, and identify the
alarmin that causes the deregulation of bone homeostasis under
inflammatory conditions.
OUTSTANDING QUESTIONS
By reviewing the involvement of alarmins in/on EVs in bone
homeostasis, we realized how many questions in this field of
research remain unanswered. Below, we highlight a couple of
these questions that require further investigation to move this
research field forward.
1) How are alarmins associated with EVs, intravesicular or
present on the outside of the vesicle membrane? And is there
preferential loading for certain types of alarmins?
Using multiple proteomics approaches, combining
proteinase treatment and biotin tagging [method published
by Cvjetkovic et al. (49)], it would be possible to delineate
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FIGURE 1 | Schematic cartoon of macrophage-derived EVs carrying alarmins impacting osteoclasts. Tissue-resident (1), circulating (2) and osteal macrophages (3)
can secrete EVs carrying alarmins (A). These vesicles can interact with bone cells, including osteoclasts (4), in a number of different ways (B). Vesicles can be
internalized (a), fuse with the cell membrane (b) or ligands present on the outer membrane of the vesicle can interact with receptors on the cellular membrane (c). The
composition and relative quantities of alarmins on macrophage-derived EVs will determine their functional effects.
which alarmins are present on the outer membrane
versus intravesicular.
2) Are alarmins associated with EVs functionally
active? And how does this activity relate to
soluble alarmins?
In vitro separation of EVs from soluble alarmins derived
from macrophages can be difficult, as this heavily depends on
the isolation techniques used. If sufficient separation can be
achieved, it will be possible to determine how effective each
fraction is.
3) In the setting of bone homeostasis, how large is the
contribution of EV-associated alarmins compared to soluble
alarmins?
To delineate the contribution of particle-bound versus
soluble alarmins we could utilize macrophage-specific
knockdown/inhibition of EV-secretion or EV-loading
mechanisms, preventing secretion of alarmin-carrying EVs
specifically for macrophages.
4) Is there a difference in alarmin content between osteomacs
and circulating macrophages? And where are alarmin-
carrying EVs produced primarily?
Comparing the cargo of osteomac- and macrophage-
derived EVs using proteomics will shed light on how the
EVs differ in alarmin content. It will however remain difficult
to trace back the cellular origin of EVs in vivo without
prior labeling of the producing cells.
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